Mattys, the CEO and Director of Tactile Systems Technology, Inc. (NASDAQ:TCMD). “Mr. Mattys: Lymphedema is a pretty horrific condition that is progressive, so it gets worse if not treated ...

Tactile Systems projects 2025 full-year revenue between $316 million and $322 million, representing an 8%-10% year-over-year growth. Guidance assumes 8%-10% growth in the Lymphedema product line ...

Tactile Systems Technology, Inc. (NASDAQ:TCMD) Q4 2024 Earnings Call Transcript February 18, 2025 Tactile Systems Technology, Inc. beats earnings expectations. Reported EPS is $0.397, expectations ...

Welcome, ladies and gentlemen, to the fourth quarter and fiscal year 2024 earnings conference call for Tactile ... included in the medical records. The requirement of a basic pump trial, even ...

For 2025, Tactile Systems projects revenue growth of 8-10%, with expectations of $316-$322 million. The company is focusing on expanding its lymphedema and airway clearance product lines and improving ...

Welcome, ladies and gentlemen, to the Fourth Quarter and Fiscal Year 2024 Earnings Conference Call for Tactile ... included in the medical records. The requirement of a basic pump trial even ...

Tactile Systems Technology Inc (NASDAQ:TCMD) reported a strong Q4 performance with total revenue of $85.6 million, marking a 10.2% year-over-year growth. The lymphedema business line saw a ...